Continuous Glucose Monitor System Market Report 2025

This Continuous Glucose Monitor System market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The continuous glucose monitor (CGM) system market size has grown rapidly in recent years. It will grow from $8.83 billion in 2024 to $9.67 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth observed during the historic period can be attributed to factors such as an expanding geriatric population, increased awareness of diabetes management, rising disposable income, higher investment in research and development, and growing healthcare expenditure.

The continuous glucose monitor (CGM) system market size is expected to see rapid growth in the next few years. It will grow to $17.0 billion in 2029 at a compound annual growth rate (CAGR) of 15.1%. The growth projected for the forecast period can be attributed to factors such as the rising prevalence of diabetes, an increase in obesity cases, socio-economic changes, a growing number of clinical trials, and increasing urbanization. Key trends expected during this period include integration with smart devices, a growing use of artificial intelligence (AI), non-invasive monitoring solutions, the expansion of wearable technology, the rise of telemedicine, and the development of remote healthcare solutions.

The growing prevalence of diabetes is expected to drive the expansion of the continuous glucose monitor (CGM) system market. Diabetes is a chronic condition characterized by elevated blood sugar levels, resulting from the body's inability to effectively produce or use insulin. The rise in diabetes is largely due to factors such as increasing obesity rates, poor dietary habits, physical inactivity, and an aging population. CGM systems provide real-time glucose readings, assisting in diabetes management by identifying trends and alerting users to abnormal glucose levels. These systems help improve glycemic control and reduce the need for frequent finger pricks. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported that in 2023, over half a million (549,000) additional individuals in England were identified as being at risk of developing type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This marked a significant increase from 3,065,825 in 2022, reflecting nearly a 20% rise. As a result, the increasing prevalence of diabetes is driving growth in the CGM system market.

Leading companies in the continuous glucose monitor (CGM) system market are working on developing advanced over-the-counter (OTC) CGMs to improve accessibility and reach non-prescription users. An OTC CGM is a device that allows individuals to track their glucose levels in real-time without requiring a prescription, providing a convenient and independent way for consumers to monitor their glucose. For example, in September 2024, Abbott Laboratories, a US-based medical device company, introduced Lingo in the United States. This device is designed for adults without diabetes, enabling users to track their glucose levels and gain valuable insights into how diet and exercise impact their overall health. With a wearability period of up to 14 days, Lingo aligns with Abbott's strategy to cater to the growing market of consumers interested in prediabetes management and wellness, all without the need for a prescription.

In August 2024, Abbott, a US-based manufacturer of continuous glucose monitors, formed a partnership with Medtronic plc to develop an integrated continuous glucose monitoring (CGM) system. The goal of this collaboration is to enhance diabetes management for millions of patients globally who depend on intensive insulin therapy. Medtronic plc, an Ireland-based medical device company, offers CGM systems as part of its product portfolio.

Major players in the continuous glucose monitor system market are Abbott Corporation, Medtronic PLC, Murata Manufacturing Co. Ltd., Dexcom Inc., Sinocare Inc., Tandem Diabetes Care Inc., Ascensia Diabetes Care Holdings AG, Glooko Inc., DarioHealth Corp., Menarini Diagnostics SRL, Senseonics Holdings Inc., WaveForm Technologies Inc., Medtrum Technologies Inc., Biolinq Incorporated, Ultrahuman Inc., GlySens Incorporated, Glucotrack, EOFLOW CO. LTD., Nemaura Medical Inc., Meiqi Medical Equipment, and Nipro Diagnostics UK Limited.

North America was the largest region in the continuous glucose monitor (CGM) system market in 2024. The regions covered in continuous glucose monitor system report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the continuous glucose monitor system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A continuous glucose monitoring (CGM) system is a medical device designed to provide real-time tracking of glucose levels for individuals with diabetes. The system typically includes a small sensor placed under the skin that measures glucose levels in the interstitial fluid, transmitting the data to a receiver or smartphone app for easy monitoring. This technology helps users make informed decisions about insulin administration and lifestyle choices to effectively manage blood sugar levels.

The main components of a continuous glucose monitoring system include transmitters, receivers, and sensors. Transmitters are devices that convert signals into a form suitable for transmission, allowing data to be sent over distances. The technology includes real-time continuous glucose monitoring and intermittently scanned continuous glucose monitoring, catering to different demographics, including children and adults. CGM systems are used for various applications, such as managing type-1 diabetes, type-2 diabetes, and gestational diabetes, and are utilized by several end users, including diagnostic centers, hospitals, clinics, intensive care units (ICUs), and home healthcare settings.

The continuous glucose monitor system market research report is one of a series of new reports that provides continuous glucose monitor system market statistics, including the continuous glucose monitor system industry global market size, regional shares, competitors with the continuous glucose monitor system market share, detailed continuous glucose monitor system market segments, market trends, and opportunities, and any further data you may need to thrive in the continuous glucose monitor system industry. These continuous glucose monitor system market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The continuous glucose monitor system market consists of revenues earned by entities by providing services such as data integration, personalized insights, and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The continuous glucose monitor (CGM) system market also includes sales of sensors, transmitters, data management software, and receivers/display devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.